Skip to main content
Premium Trial:

Request an Annual Quote

ABL, RDI Collaborate on HIV Management Tool

NEW YORK (GenomeWeb) – Advanced Biological Laboratories and the HIV Resistance Response Database Initiative (RDI) this week announced a collaboration on HIV management.

Under the agreement, data stored in ABL's health management system, TherapyEdge, can be automatically uploaded to RDI's HIV Treatment Response Prediction System (HIV-TRePS), allowing physicians to predict patient response to HIV drug combinations in seconds.

TherapyEdge assimilates longitudinal patient data, medical and clinical trial information, and international and national guidelines while HIV-TRePS uses computational models to predict the probability of success of antiretroviral drug combinations. The system was developed from data from tens of thousands of patients and makes predictions from the patient's individual data, the partners said, adding that the collaboration allows the data to be sent to HIV-TRePS automatically from TherapyEdge.

Financial and other terms of the deal were not disclosed.

HIV-TRePS will remain available to healthcare professions for free on RDI's website, ABL and RDI said.

"This is an exciting and highly logical step forward, capitalizing on the complementarity of our systems in a way that I believe is a model for the future management of many different medical conditions," Brendan Larder, scientific chair of RDI, said in a statement. "We are hopeful that the collaboration will also accelerate the collection of outcome data and enable us to develop new and further improved versions of HIV-TRePS."